GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 159   

Articles published

GSK 41.71 +0.11 (0.25%)
price chart
3-Month Weakening Healthcare Stocks: GlaxoSmithKline plc (ADR) (NYSE:GSK ...
Investors don't want to put their money into ventures that are not likely to provide at least a small return - in fact, based on an investor's needs, small returns may not be acceptable.
GlaxoSmithKline plc (ADR) Mega-Merger Talk: Johnson & Johnson, Roche Holding ...
New takeover rumors for GlaxoSmithKline Plc. (ADR) (NYSE:GSK) emerged Monday. Daily Mail UK reported that UK dealers were speculating Roche Holding Ltd.
GlaxoSmithKline plc (ADR) ViiV Healthcare Strikes Deal With China's Desano ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) is on track to bring a turnaround to its image in China, which began deteriorating following a recent bribery scandal.
GlaxoSmithKline plc (ADR) To Team Up With Francis Crick Institute For Medical ...
British pharmaceutical giant, GlaxoSmithKline plc (ADR) (NYSE:GSK) has yet another victory to add to its long established success story; the company, which seeks to enhance its focus on new scientific discoveries, announced today that it will be ...
Analytic Report on GlaxoSmithKline PLC (ADR) (NYSE:GSK)
[Financial Times] GlaxoSmithKline PLC (ADR) (NYSE:GSK)(TREND ANALYSIS) Broker theorising about a �90bn takeover was greeted with a shrug by GlaxoSmithKline shareholders.
GlaxoSmithKline plc. (ADR) (GSK) Sells Two Meningitis Vaccines To Pfizer Inc ...
The need for the said transaction arose, as GSK sought to ease the concerns of regulatory authorities. The company has recently acquired Novartis's NoMenveo and Bexsero vaccines.
Here's How Pfizer Inc., GlaxoSmithKline plc Vaccines Deal Works For Both ...  Bidness ETC
GlaxoSmithKline plc (ADR) (NYSE:GSK) Sells Two Vaccines to Pfizer Inc. (NYSE ...  WallStreetPR (blog)
GlaxoSmithKline plc (ADR) (GSK) Prepares Major Turnaround
GlaxoSmithKline plc (ADR) (NYSE:GSK) reported first-quarter fiscal'15 (1QFY15) earnings yesterday, with CEO Andrew Witty providing investors a much-needed future outlook for the company stock and a detailed 2015 guidance.
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets  WallStreetPR (blog)
GlaxoSmithKline Reports Higher Q1 Profit On Transaction Gain - Quick Facts  Nasdaq
Pfizer Inc. (PFE) Rumored To Be Eyeing British Giant GlaxoSmithKline plc (ADR)
Pfizer Inc. (NYSE:PFE) went big exactly a year ago when it announced a takeover offer for UK-based AstraZeneca plc (ADR) (NYSE:AZN). The company's decision to lap up AstraZeneca was seen as opportunistic; it being laced with controversy on many ...
Gilead Sciences, Inc. Vs. GlaxoSmithKline plc (ADR) In The HIV Drugs Race
Gilead Sciences, Inc. (NASDAQ:GILD), the undisputed leader of the fast-expanding Hepatitis C drugs market, is headed for dominating the HIV market as well.
GlaxoSmithKline plc (ADR)(NYSE:GSK) Chief Strategy Officer Foresees Success ...  WallStreet Scope
GlaxoSmithKline plc (ADR) (GSK) Stock Up 3% After New Chairman Reiterates ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) stock is trading up by nearly 3% today as the newly appointed chairman of Britain's largest drug-maker, Philip Hampton, has expressed support for the currently-pressured CEO Andrew Witty.